Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Severe COVID-19 reactivates dormant viruses and may leave a lasting viral signature

7

Aug 2026

Severe COVID-19 reactivates dormant viruses and may leave a lasting viral signature

A longitudinal study of 1,154 hospitalized COVID-19 patients found widespread reactivation of chronic Herpesviridae and Anelloviridae, with distinct viral patterns linked to disease severity, inflammation, and clinical outcomes. Anelloviridae also persisted during convalescence and were associated with physical deficits in long COVID, although the study did not establish causation.

Nicotine gum may make smokeless tobacco withdrawal easier to manage

6

Aug 2026

Nicotine gum may make smokeless tobacco withdrawal easier to manage

A randomized trial found that 2 mg nicotine gum controlled craving, anxiety, and sleep problems more effectively than behavioral counselling during smokeless tobacco cessation. Although abstinence rates were numerically higher with nicotine gum, the differences were not statistically significant, highlighting the need for larger studies.

Firearm injury patients face measurable risk of bacterial infections

6

Aug 2026

Firearm injury patients face measurable risk of bacterial infections

A new study from researchers at the University of Maryland School of Medicine (UMSOM) found that bacterial infections develop in approximately 5 percent of adults hospitalized with firearm injuries, with most infections occurring during the initial hospitalization rather than after patients return home.

Nighttime light linked to conflicting signs of biological aging

6

Aug 2026

Nighttime light linked to conflicting signs of biological aging

Higher residential nighttime light exposure was associated with contrasting biological aging patterns in nearly 300,000 UK Biobank participants, depending on the aging algorithm used. PhenoAge and homeostatic dysregulation suggested a potentially adverse aging pattern, while KDM-BA showed the opposite association, underscoring uncertainty about how nighttime light relates to biological aging.

IL-6 receptor blockers show promise for preventing MOGAD relapses

6

Aug 2026

IL-6 receptor blockers show promise for preventing MOGAD relapses

An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune neurological disorder that can cause vision loss, paralysis and other serious neurological complications.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.